Tibra Equities Europe’s Acadia Pharmaceuticals ACAD Stock Holding History

Tibra Equities Europe’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,600	Closed	-$604K	–	212
2019 Q2	$604K	Buy	+22,600	New	+$577K	0.04%	180
2018 Q4	–	Sell	-12,354	Closed	-$256K	–	181
2018 Q3	$256K	Buy	+12,354	New	+$194K	0.03%	186

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Tibra Equities Europe's ACAD Position: Q3 2019 in Review

Tibra Equities Europe sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 22,600 shares — an estimated $604K sold.

Tibra Equities Europe first reported a position in ACAD in Q3 2018 and held it in 2 quarters. The position peaked at $604K in Q2 2019. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Tibra Equities Europe reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Tibra Equities Europe sold 22,600 Acadia Pharmaceuticals shares in Q3 2019, an estimated $604K.
Tibra Equities Europe first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 2 quarters.
Tibra Equities Europe's Acadia Pharmaceuticals position peaked at $604K in Q2 2019.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.